novel technology that provides safety, consistency and performance has been developed, offering benefits to manufacturers and patients. Novozymes Hyasis is the next generation of
high-quality HA, setting the new scale of safety, consistency, and performance. Based on a next generation Bacillus-derived production process, Hyasis offers a low risk of adverse events, fewer failed batches, with greater capacity use and reduced costs for dermal filler manufacturers and latterly, the final end-user. The features of Hyasis can be advantageous as an
ingredient for dermal fillers and the final end-user. The ultra-purity and reproducible molecular properties can contribute to the safety, consistency and robustness of final products, providing optimal injection mechanics for increased practitioner convenience and patient comfort. The resulting HA material is unmatched in purity with particularly low levels of nucleic acids, proteins, bacterial endotoxins and microbial contamination, which are believed to reduce hypersensitivity reactions when the material is injected either as linear or cross-linked HA. Hyasis® Link is the new state-of-the-art proprietary
cross-linking technology for modifying the properties of HA and preparing HA hydrogels, which are versatile and well tolerated. The reproducible, safe and homogeneous hydrogels do not contain any detectable residual cross-linking agent and can withstand both autoclaving and extrusion through needles of different gauge sizes. This formulation of HA offers greater performance and patient comfort without significant alteration of their rheological properties when extruded through a needle.
Conclusions As non-surgical products and devices to correct facial contour defects and signs of skin ageing become evermore popular, dermal fillers have become a sought-after treatment in aesthetic medicine. In response to this market demand, dermal fillers are increasingly being engineered in order to enhance the safety, precision and flexibility of the correction
prime-journal.com | March 2013
ne“Hyasis is the
xt generation of high-quality
hyaluronic acid setting the new scale of safety, consistency, and performance for dermal filler
manufactures in aesthetic medicine.
”
provided. Hyasis, a Bacillus-derived HA is an innovative technology that has been designed to optimise the versatility, convenience and safety of dermal drug delivery, providing significant benefits for both practitioners and patients.
Further information Our representatives will be at the AMWC Congress, Monaco. To book a meeting or see Hyasis, the next generation Bacillus-derived HA in action, please visit
www.hyasis.com
References
1. Sturm LP, Cooter RD, Mutimer KL, Graham JC, Maddern GJ. A systematic review of dermal fillers for age-related lines and wrinkles. ANZ J Surg 2011; 81(1–2): 9–17
2. Ghersetich I, Lotti T, Campanile G, Grappone C, Dini G. Hyaluronic acid in cutaneous intrinsic aging. Int J Dermatol 1994; 33(2): 119–22
3. Oh JH, Kim YK, Jung JY et al. Intrinsic aging- and photoaging-
dependent level changes of glycoaminoglycans and their correlation with water content in human skin. J Dermatol Sci 2011; 62(3): 192–201
4. Smith L, Cockerham K. Hyaluronic acid dermal fillers: can adjunctive lidocaine improve patient satisfaction without decreasing efficacy or duration?, Dove Medical Press Ltd.
❚
123
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140